Novartis AG has received approval from the FDA for Tekturna, the first new class of drug in more than a decade approved for treating high blood pressure. The drug acts by inhibiting renin, an enzyme secreted primarily by the kidneys that raises blood pressure.

According to the company, it’s expected to be available later this month. According to the company, high blood pressure affects almost one billion people worldwide and is uncontrolled in about 70% of them. According to analysts, the drug may generate annual sales of approximately $1 billion.

Tekturna, which will be known as Rasilez outside the U.S., was developed with Swiss-based biopharmaceutical company, Speedel.